

## Accepted Manuscript

New Drugs

Targeting the Wnt/beta-catenin Pathway in Cancer: Update on Effectors and Inhibitors

Nithya Krishnamurthy, Razelle Kurzrock

PII: S0305-7372(17)30187-1

DOI: <https://doi.org/10.1016/j.ctrv.2017.11.002>

Reference: YCTRV 1699

To appear in: *Cancer Treatment Reviews Cancer Treatment Reviews*

Received Date: 28 July 2017

Revised Date: 1 November 2017

Accepted Date: 3 November 2017

Please cite this article as: Krishnamurthy, N., Kurzrock, R., Targeting the Wnt/beta-catenin Pathway in Cancer: Update on Effectors and Inhibitors, *Cancer Treatment Reviews Cancer Treatment Reviews* (2017), doi: <https://doi.org/10.1016/j.ctrv.2017.11.002>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Targeting the Wnt/beta-catenin Pathway in Cancer: Update on Effectors and Inhibitors**Nithya Krishnamurthy<sup>1</sup>. Razelle Kurzrock MD<sup>1,2</sup>**Affiliations:** <sup>1</sup>Center for Personalized Cancer Therapy, UCSD Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.<sup>2</sup>Division of Hematology-Oncology, University of California San Diego, La Jolla, CA, USA.**\*To whom correspondence should be addressed:**

Ms. Nithya Krishnamurthy  
Center for Personalized Cancer Therapy  
UC San Diego - Moores Cancer Center 3855 Health Sciences Drive, MC  
#0658  
La Jolla, California 92093-0658  
(858) 657 6410 Direct  
(858) 822 2300 Fax  
nithyamurthy9@gmail.com

**Disclosures:** Dr. Kurzrock receives research funding from Genentech, Merck, Serono, Pfizer, Sequenom, Foundation Medicine, and Guardant, as well as consultant fees from X Biotech, and Actuate Therapeutics and has an ownership interest in Curematch Inc.**Funding:** Funded in part by National Cancer Institute grant P30 CA016672 and the Joan and Irwin Jacobs Fund philanthropic fund.

Download English Version:

<https://daneshyari.com/en/article/8785933>

Download Persian Version:

<https://daneshyari.com/article/8785933>

[Daneshyari.com](https://daneshyari.com)